Preliminary results of the evaluation of the California Hub and Spoke Program
- PMID: 31400985
- DOI: 10.1016/j.jsat.2019.07.014
Preliminary results of the evaluation of the California Hub and Spoke Program
Abstract
In August 2017, California launched the Hub and Spoke Program to address the growing number of opioid overdose deaths in the state. The program connects opioid treatment programs ("hubs") with office based opioid treatment settings, like primary care clinics ("spokes") to build a network of treatment expertise and referral resources. A key objective of this program is to expand access to medications for opioid use disorders (MOUD), with a particular focus on getting more buprenorphine into spokes. This article describes the preliminary results of the evaluation of the California Hub and Spoke program. Using a mixed methods approach, this portion of the evaluation measures changes in numbers of MOUD patients and providers, and barriers and facilitators to implementation. Findings reveal that, in the first 15 months of the program, 3480 new patients started buprenorphine in 118 spokes, increasing treatment initiations by 94.7% over baseline. The number of waivered spoke providers also increased 52.4% to 268. Although these data demonstrate promising growth in the network, challenges to expanding treatment access remain. Provider activity was among the most notable. Despite growth in the number of spoke providers with waivers to prescribe buprenorphine, only 68.7% (n = 184) were actively prescribing to patients. A survey of providers found that those who were not yet using their waivers lacked the confidence and mentorship they needed to prescribe. Provider knowledge and attitudes toward MOUD, fear of legal consequences, and limited patient outreach were also contributing factors. Recommendations for strengthening Hub and Spoke program implementation include facilitating mentor linkage for prescribers, expanding the support offered to spoke providers, and offering additional training and technical assistance aimed at provider stigma. Efforts to address these recommendations are described in a companion paper (Miele et al., under review).
Keywords: Buprenorphine; California State Targeted Response; Hub and spoke; Medications for opioid use disorders; Opioid.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact.J Subst Abuse Treat. 2020 Jan;108:20-25. doi: 10.1016/j.jsat.2019.07.013. Epub 2019 Jul 27. J Subst Abuse Treat. 2020. PMID: 31399272 Free PMC article.
-
The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.J Subst Abuse Treat. 2020 Jan;108:33-39. doi: 10.1016/j.jsat.2019.07.007. Epub 2019 Jul 19. J Subst Abuse Treat. 2020. PMID: 31358328 Free PMC article.
-
Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.Prev Med. 2019 Nov;128:105785. doi: 10.1016/j.ypmed.2019.105785. Epub 2019 Jul 27. Prev Med. 2019. PMID: 31362002 Free PMC article.
-
Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.Rural Remote Health. 2015;15:3019. Epub 2015 Feb 4. Rural Remote Health. 2015. PMID: 25651434 Review.
-
Medications for management of opioid use disorder.Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105. Am J Health Syst Pharm. 2019. PMID: 31361869 Review.
Cited by
-
Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.Res Sq [Preprint]. 2024 May 3:rs.3.rs-4331201. doi: 10.21203/rs.3.rs-4331201/v1. Res Sq. 2024. PMID: 38746408 Free PMC article. Preprint.
-
Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.Drug Alcohol Depend. 2024 Mar 1;256:111125. doi: 10.1016/j.drugalcdep.2024.111125. Epub 2024 Feb 14. Drug Alcohol Depend. 2024. PMID: 38368666
-
Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial.JAMA Intern Med. 2023 Dec 1;183(12):1343-1354. doi: 10.1001/jamainternmed.2023.5701. JAMA Intern Med. 2023. PMID: 37902748
-
Toward social-health integration in Sicily: description of the first hub and spoke model to improve the diagnostic therapeutic care paths for neurorehabilitation.Front Public Health. 2023 May 16;11:1141581. doi: 10.3389/fpubh.2023.1141581. eCollection 2023. Front Public Health. 2023. PMID: 37261231 Free PMC article.
-
Opening the "black box": Four common implementation strategies for expanding the use of medications for opioid use disorder in primary care.Implement Res Pract. 2021 May 19;2:26334895211005809. doi: 10.1177/26334895211005809. eCollection 2021 Jan-Dec. Implement Res Pract. 2021. PMID: 37090014 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources